Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010

Executive Summary

Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential

You may also be interested in...



Pfizer ups BIO ante

Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...

Pfizer ups BIO ante

Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program

Related Content

UsernamePublicRestriction

Register

PS046896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel